Literature DB >> 29659205

Executive Function Predicts Antidepressant Treatment Noncompletion in Late-Life Depression.

Pilar Cristancho1,2, Eric J Lenze2, David Dixon2, J Philip Miller3, Benoit H Mulsant4, Charles F Reynolds5, Meryl A Butters5.   

Abstract

OBJECTIVE: To examine whether executive function (EF) is associated with nonremission and noncompletion of antidepressant pharmacotherapy in older adults with depression.
DESIGN: In this prospective study (July 2009 to May 2014), older adults (aged ≥ 60 years; n = 468) with a DSM-IV-defined major depressive episode diagnosed via structured interview received 12 weeks of venlafaxine extended release with the goal of achieving remission. A hypothesis was made that worse baseline EF would predict both nonremission and noncompletion (primary outcomes). Treatment-related factors, including side effects and nonadherence, were also studied.
METHODS: Baseline EF, including response inhibition and set-shifting, was assessed with subtests of the Delis-Kaplan Executive Function System and the semantic fluency subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Attention, immediate memory, delayed memory, visuospatial ability, and global cognition were also assessed with the RBANS.
RESULTS: Of 468 participants, 96 (21%) failed to complete the treatment trial, 191 (41%) completed and remitted, and 181 (39%) completed and did not remit. Univariate analyses indicated that some EFs (set-shifting and semantic fluency) and other cognitive variables (attention, immediate memory, visuospatial ability, and global cognition) predicted treatment noncompletion, whereas no cognitive variables predicted nonremission. In a multivariate logistic regression model, semantic fluency (P = .003), comorbid medical burden (P < .001), and early nonadherence (P < .001) were significant predictors of treatment noncompletion.
CONCLUSIONS: Poorer EF predicted treatment noncompletion. These findings suggest that EFs of initiation and set maintenance (examined by the semantic fluency task) may allow depressed elderly individuals to engage and stay in treatment. Identification of those at risk for noncompletion may help implementation strategies for personalized care. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00892047. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29659205     DOI: 10.4088/JCP.16m11371

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

Review 1.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

2.  Treatment Adequacy and Adherence as Predictors of Depression Response in Primary Care.

Authors:  Jo Anne Sirey; Alexandra Woods; Nili Solomonov; Lauren Evans; Samprit Banerjee; Paula Zanotti; George Alexopoulos; Helen C Kales
Journal:  Am J Geriatr Psychiatry       Date:  2020-04-23       Impact factor: 4.105

3.  Comorbid anxiety in late-life depression: Relationship with remission and suicidal ideation on venlafaxine treatment.

Authors:  Yasmina M Saade; Ginger Nicol; Eric J Lenze; J Philip Miller; Michael Yingling; Julie Loebach Wetherell; Charles F Reynolds; Benoit H Mulsant
Journal:  Depress Anxiety       Date:  2019-11-04       Impact factor: 6.505

4.  Predicting Medication Nonadherence in Older Adults With Difficult-to-Treat Depression in the IRL-GRey Randomized Controlled Trial.

Authors:  Helene M Altmann; Joseph Kazan; Marie Anne Gebara; Daniel M Blumberger; Jordan F Karp; Eric J Lenze; Benoit H Mulsant; Charles F Reynolds; Sarah T Stahl
Journal:  Am J Geriatr Psychiatry       Date:  2022-03-10       Impact factor: 7.996

5.  Depressive symptoms may be associated with semantic memory decline in elderly adults.

Authors:  Mariana Faoro; Amer Cavalheiro Hamdan
Journal:  Dement Neuropsychol       Date:  2021 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.